EMEA gives go-ahead to first advanced therapy
This article was originally published in RAJ Devices
Executive Summary
A cell-based medicine for repairing knee damage has become the first product to be recommended for approval by the European Medicines Agency under the European Union’s new advanced therapy regulatory framework1.